Background: This study investigated the safety, pharmacokinetics (PK) and clinical antitumor activity of ABT-751, a novel sulfonamide antimitotic and vascular disrupting agent, in combination with docetaxel (Taxotere) in patients with castration-resistant prostate cancer (CRPC). expanded. Overall, severe adverse events occurred more commonly on DL 4 than 3 (47% versus 18% of patients). PK data for docetaxel and ABT-751 were similar to reported literature. Best post-treatment prostate-specific antigen decline of ‡50% occurred in 60% and objective responses occurred in 45% of patients. Median overall survival was 24 months (95% confidence interval 8.3-37.7 months).
introduction
Prostate cancer is the most common cancer in men and the second leading cause of death from cancer in North America [1] . Approximately 219 000 patients were newly diagnosed with prostate cancer and 27 000 prostate cancer deaths are estimated to have occurred in 2007 in the United States. Although $80% of all prostate cancer patients are cured of their disease by modern treatment approaches, a fifth of the patients present with either advanced-stage disease or recurrent disease for which no curative treatment options exist in general. Androgen deprivation strategies lead to responses in the overwhelming majority of these patients, but clinical benefits are limited by the emergence of castration-resistant prostate cancer (CRPC). CRPC is responsible for almost all prostate cancer-related deaths and therefore represents an important clinical challenge.
In 2004, docetaxel-based chemotherapy was introduced as standard treatment in patients with CRPC due to a statistically significant improvement in median survival and improved palliative responses and quality-of-life parameters compared with mitoxantrone [2, 3] . In those studies, median survival for patients receiving docetaxel was 19-20 months, and a posttreatment prostate-specific antigen (PSA) decline of ‡50% occurred in $45% to 50% patients. A 30% PSA decrease within 3 months of chemotherapy treatment was later described to predict for a statistically significant favorable survival outcome [4, 5] . Attempts to improve upon this benefit are underway with rational combination strategies of docetaxel with various targeted therapies.
ABT-751 is a novel oral sulfonamide antimitotic agent that binds to the colchicine site of b-tubulin in a manner distinct from that of the taxanes. Broad-spectrum preclinical activity results included activity against paclitaxel-and vincristineresistant tumors [6] . In addition, ABT-751 appears to work as a vascular disrupting agent (VDA) thereby reducing tumor blood flow to enhance the cytotoxic effect [7, 8] . This action is pertinent for patients with CRPC since targeting tumor vasculature appears an attractive treatment strategy. Overexpression of vascular endothelial growth factor (VEGF) is related to progression of prostate cancer and elevated circulating VEGF level is a poor prognostic marker [9] . Combination of docetaxel and ABT-751 therapy had at least additive activity in xenograft models including the androgeninsensitive PC-3 prostate cancer model [10] . In phase I trials, the dose-limiting toxicities (DLTs) observed with ABT-751 were peripheral neuropathy, ileus and fatigue [8, 11, 12] . The recommended single-agent phase II dose was 200 mg daily on a 21/28-day schedule and is currently being evaluated in a number of phase II trials. Notably, significant bone marrow suppression has not been observed with single-agent ABT-751 therapy, an important consideration in patients with CRPC due to their advanced age and preexisting marrow dysfunction resulting from bone metastases and prior radiation therapy. Given the above, a combination of ABT-751 and docetaxel represented a rational combination in patients with CRPC and was evaluated in this phase IB trial.
patients and methods

study design
This prospective, open-label, phase IB study was conducted at four Cancer Centers of the British Columbia Cancer Agency in the Province of British Columbia, Canada, from February 2005 to December 2007. Research Ethics Board and institutional review boards approved the protocol.
Eligible patients had histologically confirmed cancer of the prostate which had progressed despite castrate levels of testosterone and were off antiandrogen therapy. Patients were required to have measurable or evaluable radiologic or clinical evidence of metastatic or locally advanced disease, Eastern Cooperative Oncology Group performance status of two or less and adequate bone marrow and organ function (hemoglobin >90 g/l, absolute granulocytes ‡1.5 · 10 9 /l, platelets ‡100 · 10 9 /l, normal bilirubin, serum creatinine £2· the upper limit of normal and aspartate aminotransferase/alanine aminotransferase £1.5· the upper limit of normal). Patients were permitted to have had a maximum of one prior chemotherapy regimen and were enrolled in this study ‡4 weeks after external beam irradiation. Patients were ineligible if one of the following criteria was present: allergy to sulfa medication, grade 1 or higher neurological category findings, higher than grade 2 constipation at baseline, history of ileus, current treatment with colchicine, brain or leptomeningeal metastasis or serious concurrent medical conditions.
protocol treatment three to six experienced DLT. The recommended phase II dose was defined as the DL below the MTD at which no more than one patient experienced DLT; however, cumulative toxicity was also to be considered. Following the dose-escalation phase of the study, an additional six to nine patients were to be accrued to the expansion phase of this trial to better define toxicity and clinical activity.
patient evaluation
At baseline, all eligible patients underwent a physical examination and assessment of hematology, biochemistry and PSA within 14 days of study treatment. Baseline imaging (computed tomography, bone scan and chest Xray) was carried out within 28 days before registration and treatment was started within 5 days of registration. Evaluation on protocol was weekly during cycle 1, then every 3 weeks for subsequent cycles. Radiology assessments were carried out every second cycle. Plasma samples for PK analyses were obtained for ABT-751 and docetaxel during cycle 1. PSA response was defined as a decline, by at least 50%, of the baseline PSA level assessed immediately before treatment and confirmed by a second PSA level at least 3 weeks later [13] . Response Evaluation Criteria in Solid Tumors (RECIST) were used for the evaluation of response [14] . Adverse events were graded according to Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0.
PK
Analytical determination of docetaxel was conducted using a validated high-performance liquid chromatography-mass spectrometry assay. Plasma samples were collected before dose and after the start of infusion at 1, 2, 4, 6, 8, 24 and 48 h. Noncompartmental PK analysis was carried out on the plasma concentration data including assessment of the time to reach peak plasma concentration, (T max ), observed maximum plasma concentrations (C max ), area under the plasma concentration-time curve (AUC 0-48 ), terminal elimination half-life (t ½ ) and total plasma clearance using WinNonlin (Version 3.2; Pharsight Corporation, Mountain View, CA) computer software.
Plasma samples were collected for the analytical determination of ABT-751 and its metabolites (glucuronide and sulfate) at 0 (before dose), 0.25, 0.5, 1, 2, 4, 6, 9 and 24 h. Plasma concentrations of ABT-751 and its metabolites were determined using validated liquid chromatography with tandem mass spectrometry detection assay methodology. The following PK parameters were determined using noncompartmental methods in WinNonlinÒ computer software (Version 5.2; Pharsight Corporation) for ABT-751 and its metabolites: the observed maximum plasma concentration (C max ), time to C max (T max ) and area under the plasma concentration-time curve from time 0 to 9 h (AUC 0-9 ).
statistical analysis
Descriptive statistics was conducted by Mann-Whitney test for a limited number of variables. P value £0.05 (two sided) was considered statistically significant. Survival was estimated by the method of Kaplan and Meier. The statistical software SPSSÒ for Windows (version 11; SPSS Inc., Chicago, IL) was used. In total, 32 patients were accrued and all patients received at least one cycle of treatment. Eighteen patients were treated on the dose-escalation phase and an additional 14 patients received treatment on the expansion phase. The baseline characteristics of the population were typical of patients with CRPC treated with chemotherapy and are listed in Table 2 . The median age was 67 years (range 55-79) and almost all had bone metastases (94%). Five patients had prior systemic chemotherapy including prior docetaxel (four patients).
treatment delivered
All enrolled patients completed study treatment. The total number of cycles delivered to all patients was 237 with a median number of 8.5 treatment cycles delivered per patient (range 1-10). The median number of cycles in patients treated at 60 mg/m 2 docetaxel (DLs 1-3) was 9(range 1-10) and eight (range 1-10) in patients receiving 75 mg/m 2 (DL 4). One patient each on DL 3 (docetaxel 60 mg/m 2 + ABT-751 200 mg) and on DL 4 (docetaxel 75 mg/m 2 + ABT-751 200 mg) experienced a DLT (febrile neutropenia and grade 3 diarrhea/ nausea/neutropenia, respectively). These DLs were initially expanded to six patients, each with no additional DLT observed. Thus, the MTD was not observed at the DLs tested and both DLs 4 and 3 were then further expanded (with an additional nine and five patients, respectively) to better describe safety and tolerability.
adverse events
Analysis of toxicity experienced by patients treated on both the dose-escalation and expansion phase of the study revealed that at DL 4, 7 of 15 patients (47%) required dose reduction due to severe treatment-related toxicity and there was one death on protocol therapy. This patient was admitted with treatmentrelated severe neutropenia, diarrhea and dehydration following his first cycle of therapy. He recovered but subsequently developed small-bowel obstruction requiring laparotomy and lysis of adhesions. His postoperative course was complicated by methicillin-resistant Staphylococcus aureus sepsis, from which he died. DL 3 was then expanded by five patients (total 11 patients) and three patients (18%) required dose reduction for severe treatment-related adverse events at this DL.
In terms of non-hematologic adverse events, the most common of any grade were fatigue, alopecia, diarrhea, sensory peripheral neuropathy and taste alterations, which occurred in most patients and were predominantly mild-moderate in severity (Table 3) . Episodes of grade 3 or 4 non-hematologic toxicity were infection (19%), diarrhea (16%) and nausea/ vomiting/syncope, which affected two patients each (Table 4) . Most of these episodes occurred acutely, i.e. following the first cycle of treatment (18 of the 31 grade 3-4 adverse events), and affected patients treated at DL 4 (21 of the 31 grade 3-4 adverse events). Ten episodes of grade 3-4 therapy-related adverse effects were observed in patients treated at DL 3 and 80% of those occurred after cycle 1.
Grade 3 and 4 hematologic adverse events are listed in Table  4 . In total, 53% of patients (17 of 32) developed grade 3 or 4 neutropenia during therapy, and all but one episode was detected during the first cycle of treatment. Severe neutropenia was recorded in 13 of 15 patients at DL 4 (87%) compared with 3 of 11 patients (27%) at DL 3 and in one of six patients treated at DL 1 and 2 (17%). There were no grade 3 or 4 anemia or thrombocytopenia events observed. The mean drop of hemoglobin concentration or platelet count during treatment was <20% with no difference between DLs.
PK analyses
PK sampling was carried out in all 18 patients on the doseescalation phase of the study (Table 5) . ABT-751 PK parameters demonstrated that plasma concentration and systemic exposure were dose proportional and unaffected by increasing docetaxel dosage. There was no evident difference in mean t ½ , C max and AUC levels for docetaxel at 60 mg/m 2 at different ABT-751 dosing. The mean maximum plasma concentration (2.98 6 1.08 lg/ml versus 1.53 6 0.35 lg/ml, P = 0.002) and systemic exposure (3.92 6 1.19 lgÁh/ml versus 2.28 6 0.58 lgÁh/ml, P = 0.006) of docetaxel at 75 mg/m 2 were significantly higher compared with 60 mg/m 2 at the same 200-mg ABT-751 dosing. The interpatient variability in C max and AUC, as reflected by value of standard deviation, appeared more pronounced at the higher docetaxel dosage compared with 60 mg/m 2 dosing. In contrast, the mean beta half-life for docetaxel at both DLs was similar.
clinical outcome
All participating patients were monitored in an intention-to-treat method for clinical outcomes. The median follow-up period was 16 months (range 1-36 months). At the time of this analysis, the disease had progressed in 30 of 32 (93%) patients and 16 of 32 (50%) patients had died. Maximum post-treatment PSA decline for individual patients is illustrated in Figure 1 . Of 30 assessable patients, 18 (60% total) patients achieved a best PSA reduction of ‡50%, which was confirmed in 16 patients (53% of assessable patients); two patients had no confirmatory PSA after 3 weeks. Twenty-two of 30 assessable patients (73%) had a 30% PSA reduction within 3 months after starting protocol therapy. Best response according to RECIST criteria in 20 patients with measurable disease was as follows: nine patients (45%) had objective response [one complete response, unconfirmed, plus eight partial response (PR), two unconfirmed] and a further 10 patients (50%) had stable disease; only one patient progressed by RECIST criteria while on therapy. The median time to progression in all patients was 9 months (95% confidence interval (CI) 6.8-11.3 months) and the median overall survival time was 24 months (95% CI 8.3-37.7 months). All the five patients who had received prior chemotherapy (one mitoxantrone and four docetaxel) achieved >50% maximum PSA response, and two of three patients with measurable disease in this previously treated group had a PR (one mitoxantrone and one docetaxel).
discussion
In patients with CRPC, the combination of ABT-751 and docetaxel appeared generally well tolerated, and the overall clinical outcome parameters were encouraging. As protocol defined, the MTD was not observed with the combination of ABT-751 at its recommended phase II dose and docetaxel at the standard dose used in patients with CRPC. The recommended phase II dosing was projected to be DL 4 (docetaxel at 75 mg/m 2 , ABT-751 200 mg daily for 14 days) based on the favorable sideeffect profile seen in patients on the dose-escalation phase. However, cumulative safety analysis including patients treated on 
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the expansion phase revealed a higher incidence of severe treatment-related adverse events warranting early dose reductions on DL 4 as compared with patients treated at the lower dose of docetaxel. Thus, based on the cumulative toxicity profile, the recommended phase II combination dose of ABT-751 is 200 mg daily with docetaxel 60 mg/m 2 for this patient population. Adverse events observed on this study included not only grade 3 and 4 fatigue and asthenia, diarrhea and nausea but also severe neutropenia and infections. The former have been commonly reported as DLTs in single-agent ABT-751 studies in solid tumor patients but are also recognized side-effects of docetaxel when given at the 75 mg/m 2 dosage while severe neutropenia and infections are not commonly encountered with ABT-751 [2, 8, 11] . The relatively high incidence of grade 3 gastrointestinal adverse events (5 of 26 patients at DL 3 and 4 developed severe diarrhea including one patient who died later from mechanical ileus and postoperative sepsis) may point to an additive toxic effect.
Although cardiac function was not formally assessed, there were no clinically evident cardiovascular adverse events observed on study with the exception of one patient who developed temporary grade 3 heart failure during a hospital admission for neutropenic sepsis. Preclinical and more recent clinical findings raise the potential concern of cardiac side-effects with VDA [7, 8, 15] , therefore requesting formal cardiac safety assessments with future studies involving VDA. Future trials with ABT-751 should also consider exploring the use of potential biomarkers of VDA effects, such as peripheral blood measurements of circulating endothelial cell and circulating endothelial cell progenitors as has been indicated by Yee et al. [8] .
Metabolism of ABT-751 occurs primarily by glucuronidation and sulfation, with minimal involvement of cytochrome P-450 oxidative enzymes. In this study, PK parameters for docetaxel and ABT-751 when given in combination were similar to those found in the literature for the single agents [11, 16, 17] . PK analysis of 75 mg/m 2 docetaxel dosing revealed perhaps a higher than expected increase of docetaxel AUC and C max and reduction in clearance when compared with 60 mg/m 2 dosage. However, it is known that interpatient variation of docetaxel exposure and clearance can be marked and linked to treatment toxicity [17, 18] . Such PKs variability was particularly observed in this study at DL 4, and this finding therefore represents a likely explanation for the higher than expected incidence of severe treatment-related side-effects at the 75 mg/m 2 dosing of docetaxel. An unrecognized PK interaction between docetaxel and ABT-751 remains a possible contributing factor for the higher than expected toxicity, especially at the higher docetaxel dosage.
Despite the higher toxicity observed at DL 4, the median number of treatment cycles given was similar, irrespective of DL. This likely indicates a successful dose reduction strategy but also demonstrates the cumulative tolerability of the combination. A similar median number of cycles were delivered in the landmark trials, which also had incorporated a 10-cycle maximum limit and confirmed docetaxel as standard treatment in patients with CRPC [2, 3] . Patient baseline characteristics and prognostic factors for CRPC on this study appeared similar to those reported trials. It was encouraging to observe a median progression-free and overall survival of 9 and 24 months, respectively, in our study. In addition, the objective response rate was 45%, and posttreatment PSA declines of ‡30% and ‡50% occurred in 73% and 53% of patients, respectively, in the presented study. Despite the small number of patients, it is also interesting to note that all patients who had received prior chemotherapy had a PSA response and two of three assessable patients who had received prior chemotherapy also had an objective response.
In summary, the combination of docetaxel and ABT-751 has a favorable adverse event profile and encouraging clinical activity in patients with CRPC. Docetaxel at a starting dose of 75 mg/m 2 can be given safely with ABT-751 at 200 mg daily; however, taking into account cumulative tolerability issues, a recommended phase II dose for the combination with docetaxel starting at 60 mg/m 2 and ABT-751 at 200 mg daily for 14 days repeated at 21-day intervals should be considered. Further studies of this combination in patients with CRPC are warranted. 
